
    
      [18F]-FDG PET/MR will be performed in the Department of Nuclear Medicine - Pitié-Salpêtrière
      Hospital:

        -  prior to initiation of chemotherapy (rituximab, methotrexate, procarbazine, vincristine
           and cytarabine) (PET#1),

        -  after two chemotherapy cycles (PET#2),

        -  at the end of the first-line chemotherapy regimens (PET#3).
    
  